New indication

Colin Kerr

Posted: Wednesday, May 1, 2019

ILUVIEN® has been approved for use in UK patients for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

“This indication for ILUVIEN was based on data from two three-year, double-masked, prospective sham-controlled studies, PSV-FAI-001 and PSV-FAI-005, in 282 patients with NIU-PS, randomised 2:1 (ILUVIEN:sham). Published data from the PSV-FAI-001 study have shown ILUVIEN to be superior when compared to treated sham for multiple study outcomes, including the primary outcome of recurrence of NIU-PS at six months (27.6% ILUVIEN vs 90.5% sham, p<0.001),” said a spokesman for Alimera Sciences, manufacturers of ILUVIEN.

Latest Articles

escrs members advert